ADAP Adaptimmune Therapeutics PLC

Price (delayed)

$1.58

Market cap

$359.57M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.48

Enterprise value

$292.1M

Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform ...

Highlights
Adaptimmune Therapeutics's EPS has soared by 56% YoY and by 11% from the previous quarter
Adaptimmune Therapeutics's net income has increased by 46% YoY but it has decreased by 4.6% QoQ
The debt has grown by 14% year-on-year but it has declined by 2.8% since the previous quarter
Adaptimmune Therapeutics's equity has decreased by 30% from the previous quarter and by 22% YoY
The company's quick ratio fell by 28% YoY and by 21% QoQ

Key stats

What are the main financial stats of ADAP
Market
Shares outstanding
227.58M
Market cap
$359.57M
Enterprise value
$292.1M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.06
Price to sales (P/S)
5.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.11
Earnings
Revenue
$71.08M
EBIT
-$92.22M
EBITDA
-$83.81M
Free cash flow
-$131.43M
Per share
EPS
-$0.48
Free cash flow per share
-$0.58
Book value per share
$0.39
Revenue per share
$0.31
TBVPS
$1.31
Balance sheet
Total assets
$296.64M
Total liabilities
$208.51M
Debt
$25.6M
Equity
$88.13M
Working capital
$144.22M
Liquidity
Debt to equity
0.29
Current ratio
2.92
Quick ratio
2.2
Net debt/EBITDA
0.81
Margins
EBITDA margin
-117.9%
Gross margin
100%
Net margin
-133.9%
Operating margin
-164.8%
Efficiency
Return on assets
-30.3%
Return on equity
-100.1%
Return on invested capital
-55.1%
Return on capital employed
-41.6%
Return on sales
-129.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ADAP stock price

How has the Adaptimmune Therapeutics stock price performed over time
Intraday
6.76%
1 week
31.67%
1 month
116.44%
1 year
-7.06%
YTD
99.24%
QTD
99.24%

Financial performance

How have Adaptimmune Therapeutics's revenue and profit performed over time
Revenue
$71.08M
Gross profit
$71.08M
Operating income
-$117.13M
Net income
-$95.2M
Gross margin
100%
Net margin
-133.9%
The net margin has surged by 87% year-on-year but it has declined by 4.1% since the previous quarter
ADAP's operating margin has soared by 84% YoY but it is down by 2.7% QoQ
Adaptimmune Therapeutics's net income has increased by 46% YoY but it has decreased by 4.6% QoQ
ADAP's operating income is up by 35% YoY but it is down by 3.2% from the previous quarter

Growth

What is Adaptimmune Therapeutics's growth rate over time

Valuation

What is Adaptimmune Therapeutics stock price valuation
P/E
N/A
P/B
4.06
P/S
5.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.11
Adaptimmune Therapeutics's EPS has soared by 56% YoY and by 11% from the previous quarter
ADAP's price to book (P/B) is 81% higher than its last 4 quarters average of 2.1 and 73% higher than its 5-year quarterly average of 2.2
Adaptimmune Therapeutics's equity has decreased by 30% from the previous quarter and by 22% YoY
The P/S is 96% below the 5-year quarterly average of 117.8 but 18% above the last 4 quarters average of 4.0

Efficiency

How efficient is Adaptimmune Therapeutics business performance
Adaptimmune Therapeutics's ROS has soared by 87% YoY but it has decreased by 3.9% from the previous quarter
Adaptimmune Therapeutics's return on assets has increased by 30% YoY but it has decreased by 7% QoQ
The company's return on invested capital rose by 19% YoY but it fell by 13% QoQ
The return on equity has declined by 12% since the previous quarter but it is up by 11% year-on-year

Dividends

What is ADAP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ADAP.

Financial health

How did Adaptimmune Therapeutics financials performed over time
ADAP's total assets is 42% greater than its total liabilities
The company's quick ratio fell by 28% YoY and by 21% QoQ
ADAP's current ratio is down by 27% YoY and by 15% QoQ
The debt is 71% smaller than the equity
ADAP's debt to equity is up by 45% year-on-year and by 38% since the previous quarter
Adaptimmune Therapeutics's equity has decreased by 30% from the previous quarter and by 22% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.